Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Ann Surg. 2022 Jun 27;276(3):450–462. doi: 10.1097/SLA.0000000000005558

Figure 6: PDOs derived from matched pre- and post-NAT reveal emergence of resistance.

Figure 6:

Schematic describing collection of matched PDOs: hF161 and hT220. B) Dose response curves for hF161 (orange) and hT220 (red) for NAT the patient received: gemcitabine and paclitaxel. Flattening of paclitaxel curve is driven by emergence of resistant cells as highlighted in the graph. C) Table displaying the predicted sensitivity and resistance which was determined for the 5 chemotherapies based on the PDO biobank Tiriac et al. 7